I agree, violently. Protecting the researching company's incentives is hugely important. Otherwise we're getting the current crop of drugs at the expense of fut

I agree, violently. Protecting the researching company's incentives is hugely important. Otherwise we're getting the current crop of drugs at the expense of future drugs. Eminent domain requires "just compensation" that courts interpret as fair market value. Since the company that created the drug was recently acquired there's a really easy number to put on it.